New drug for relapsed B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has come back after at least two prior treatments. It may help if you've already had rituximab or a similar antibody therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have B-cell non-Hodgkin lymphoma (not lymphoma starting in the brain, CLL, or Burkitt lymphoma).
- You have had at least 2 previous chemotherapy treatments and also received rituximab or another anti-CD20 antibody.
- Your cancer is measurable (a lymph node larger than 1.5 cm or other tumor larger than 1 cm, or lymphoma cells in the bone marrow).
- You are in good physical condition (able to do daily activities without help).
- You agree to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs for people with a slow-growing form of non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to see if this new combination can help shrink tumors or slow the disease.
This trial tests an investigational cell therapy that targets two markers (CD20 and CD19) on your lymphoma cells. It may be an option if your B-cell lymphoma has come back or not responded to prior treatments.
This trial tests a new cell therapy called CT1190B for people with certain types of B-cell lymphoma that have come back or not responded to at least two prior treatments. It aims to see if this therapy can help control the cancer.
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
This trial tests a new T-cell therapy (EB103) for people with B-cell non-Hodgkin's lymphoma that has come back or stopped responding to treatment. It aims to see if the therapy is safe and effective.
This trial tests a new treatment made from your own immune cells (gamma-delta T cells) that are engineered to find and kill CD19-positive lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma whose cancer has not responded to or has returned after at least two standard treatments.
Hear when a new Relapsed B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.